Alim R. Devani

Calgary, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy.

Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy.

Journal: Journal of cutaneous medicine and surgery

Published: June 05, 2026

Application of Real-World Effectiveness Outcomes of Upadacitinib to Canadian Treat-to-Target Criteria in Atopic Dermatitis: A Retrospective Multicenter Analysis of 1-Year Data.

Application of Real-World Effectiveness Outcomes of Upadacitinib to Canadian Treat-to-Target Criteria in Atopic Dermatitis: A Retrospective Multicenter Analysis of 1-Year Data.

Journal: Journal of the American Academy of Dermatology

Published: April 20, 2026

Practical Considerations for the Recognition and Assessment of Chronic Hand Eczema.

Practical Considerations for the Recognition and Assessment of Chronic Hand Eczema.

Journal: Journal of cutaneous medicine and surgery

Published: March 19, 2026

OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data.

OX40 Ligand Inhibitors for Moderate-to-Severe Atopic Dermatitis: A Review of Phase II Clinical Trial Data.

Journal: Skin therapy letter

Published: December 10, 2025

Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study.

Efficacy and safety of ruxolitinib cream for the treatment of moderate to severe chronic hand eczema: Results from a 16-week, multicenter, randomized, double-blind study.

Journal: Journal of the American Academy of Dermatology

Published: April 22, 2025

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.

Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.

Journal: American journal of clinical dermatology

Published: January 12, 2025

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.

Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.

Journal: Journal of the American Academy of Dermatology

Published: December 13, 2024

Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review".

Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review".

Journal: Journal of the American Academy of Dermatology

Published: November 19, 2024

Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review.

Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Long-Term (Week 52) Data from a Real-World Multicenter Retrospective Review.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: October 24, 2024

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review.

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 52-week multicenter retrospective review.

Journal: Journal of the American Academy of Dermatology

Published: July 03, 2024

Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8-20) Data from a Real-World Multicenter Retrospective Review.

Effectiveness and Safety of Upadacitinib in Adolescent and Adult Patients with Atopic Dermatitis: An Analysis of Short-Term (Week 8-20) Data from a Real-World Multicenter Retrospective Review.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: June 24, 2024

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.

Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review.

Journal: Journal of the American Academy of Dermatology

Published: May 31, 2024

Showing 1-12 of 29

Last Updated: 09/26/2026